Literature DB >> 19727767

Gastrointestinal stromal tumors.

Maureen J O'Sullivan1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19727767     DOI： 10.1007/s00383-009-2477-9

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN： 0179-0358            Impact factor:   1.827


× No keyword cloud information.
  55 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

3.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

4.  Comparative analysis of four histopathological classification systems to discriminate benign and malignant behaviour in gastrointestinal stromal tumors.

Authors:  D Vallböhmer; H E Marcus; S E Baldus; J Brabender; G Lurje; U Drebber; R Metzger; A H Hölscher; P M Schneider
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

5.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

6.  Gastric stromal tumors. Reappraisal of histogenesis.

Authors:  M T Mazur; H B Clark
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

Review 7.  Targeting insulin-like growth factor 1 receptor in sarcomas.

Authors:  Katia Scotlandi; Piero Picci
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

8.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

Authors:  Katherine A Janeway; Bernadette Liegl; Amy Harlow; Claudia Le; Antonio Perez-Atayde; Harry Kozakewich; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

10.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466
View more
  1 in total

1.  Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST].

Authors:  Lorna Kelly; Kenneth Bryan; Su Young Kim; Katherine A Janeway; J Keith Killian; Hans-Ulrich Schildhaus; Markku Miettinen; Lee Helman; Paul S Meltzer; Matt van de Rijn; Maria Debiec-Rychter; Maureen O'Sullivan
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.